IN10018 Combination Therapy in Treatment-naïve ES-SCLC
A phase 1/2 trial of IN10018, Tislelizumab, Carboplatin in small-cell lung cancer, run by InxMed (Shanghai) Co., Ltd., now recruiting.
Overview
IN10018 Combination Therapy in Treatment-naïve ES-SCLC is a phase 1/2 interventional study registered as NCT06030258 by InxMed (Shanghai) Co., Ltd., with 120 participants planned, started 2023-10-30 and due to reach its primary completion in 2025-12-24. Interventions recorded: IN10018, Tislelizumab, Carboplatin, Etoposide. Conditions listed: Small Cell Lung Cancer Extensive Stage. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialIN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer
Shares InxMed (Shanghai), IN10018.
- TrialA Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Pa
Shares Tislelizumab, Etoposide, Carboplatin, Small-cell lung cancer.
- TrialIN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurren
Shares InxMed (Shanghai), IN10018.
- TrialA Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
Shares InxMed (Shanghai), IN10018.
- TrialDAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment
Shares Etoposide, Carboplatin, Small-cell lung cancer.
- TrialStudy of AZD2811 + Durvalumab in ES-SCLC
Shares Etoposide, Carboplatin, Small-cell lung cancer.
- TrialAK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
Shares Tislelizumab, Carboplatin, Small-cell lung cancer.
- TrialA Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer
Shares Etoposide, Carboplatin, Small-cell lung cancer.